EGFR-TKI靶向治疗联合放疗对EGFR突变型非小细胞肺癌脑转移的疗效分析

The efficacy of EGFR-TKI targeted treatment combined with radiotherapy for patients with EGFR-mutated non-small cell lung cancer with brain metastasis

目的分析表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗联合放疗对表皮生长因子受体(EGFR)突变型非小细胞肺癌脑转移的疗效。方法 2016年1月至2018年3月收治的EGFR突变型非小细胞肺癌脑转移患者90例,按随机数表法分为对照组和观察组各45例。对照组给予单纯放疗治疗,观察组在上述基础上,给予EGFR-TKI靶向治疗。治疗3个月。观察两组治疗效果、生存情况及不良反应。结果观察组总有效率高于对照组,差异有统计学意义(P <0. 05)。观察组的无进展生存时间(PFS)及总生存时间(OS)明显长于对照组,且1年生存率和2年生存率显著高于对照组,差异有统计学意义(P <0. 05)。两组不良反应率比较,差异无统计学意义(P> 0. 05)。结论 EGFR-TKI靶向治疗联合放疗对EGFR突变型非小细胞肺癌脑转移患者效果显著,可明显提高患者的生存质量,减少不良反应发生率,值得临床推广应用。

To investigate the efficacy of EGFR-TKI targeted treatment combined with radiotherapy for patients with EGFR mutated non-small cell lung cancer(NSCLC)with brain metastasis.Ninety patients with EGFR mutated NSCLC with brain metastasis treated from January 2016 to March 2018 were randomly divided into observation or control group,45 in each group.The control group was given radiotherapy alone while the observation group was received EGFR-TKI targeted treatment in addition to radiotherapy.The treatment course was 3 months.The treatment effect,survival status and adverse reactions were compared between the two groups.The total efficiency rate of the observation group was significantly higher than that of the control group(P<0.05).The no progress free survival(PFS)time and total survival(OS)time and 1-year survival rate and 2-year survival rate of the observation group were significantly longer and higher than those of the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).EGFR-TKI targeted therapy combined with radiotherapy has a significant effect on EGFR-mutated NSCNC patients with brain metastases.The treatment can significantly improve the quality of life of the patients and reduce the incidence of adverse reactions.It is worthy of popularization and application in clinical practice.